Secreted frizzled-related protein 4 inhibits proliferation and metastatic potential in prostate cancer

Prostate

Volumn 67, Issue 10, 2007, Pages 1081-1090

  Horvath, Lisa G ^a,b   Lelliott, Jayne E ^b   Kench, James G ^b,c   Lee, C Soon ^a,d   Williams, Elizabeth D ^e   Saunders, Darren N ^b   Grygiel, John J ^b   Sutherland, Robert L ^b   Henshall, Susan M ^b,f  

^a ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^b ST VINCENT S HOSPITAL   (Australia)

^c WESTMEAD HOSPITAL   (Australia)

^d UNIVERSITY OF SYDNEY   (Australia)

^e MONASH UNIVERSITY   (Australia)

^f GARVAN INSTITUTE OF MEDICAL RESEARCH   (Australia)

Author keywords

Invasiveness; Proliferation; Prostate cancer; Secreted frizzled related proteins (sFRP4); Wnt pathway

Indexed keywords

ANDROGEN; ANDROGEN RECEPTOR; BETA CATENIN; CELL ADHESION MOLECULE; FRIZZLED PROTEIN; NERVE CELL ADHESION MOLECULE; REGULATOR PROTEIN; SECRETED FRIZZLED RELATED PROTEIN 4; UNCLASSIFIED DRUG; UVOMORULIN; WNT PROTEIN;

ANCHORAGE INDEPENDENT GROWTH; ARTICLE; CANCER CELL CULTURE; CELL INVASION; CELL MEMBRANE; CELL PROLIFERATION; CELL STRUCTURE; CELLULAR DISTRIBUTION; EPITHELIOID CELL; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; METASTASIS; PHENOTYPE; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN SECRETION; SIGNAL TRANSDUCTION;

BETA CATENIN; CADHERINS; CELL LINE, TUMOR; CELL PROLIFERATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; PHENOTYPE; PROSTATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS; RECEPTORS, ANDROGEN; SIGNAL TRANSDUCTION; WNT PROTEINS;

EID: 34250861254     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.20607     Document Type: Article

References (49)

1. Tracey E, Chen W, Sitas F. Cancer in New South Wales: Incidence and mortality 2002. 2004.
2. Jemal A, Murray T, Samuels A, Ghafoor A, Ward E, Thun MJ. Cancer statistics, 2003. CA Cancer J Clin 2003;53:5-26.
3. Scher HI, Steineck G, Kelly WK. Hormone-refractory (D3) prostate cancer: Refining the concept. Urology 1995;46(2):142-148.
4. Tilley WD, Buchanan G, Hickey TE, Bentel JM. Mutations in the androgen receptor gene are associated with progression of human prostate cancer to androgen independence. Clin Cancer Res 1996;2:277-286.
5. Bubendorf L, Kononen J, Koivisto P, Schraml P, Moch H, Gasser TC, Willi N, Mihatsch MJ, Sauter G, Kallioniemi OP. Survey of gene amplifications during prostate cancer progression by high-throughout fluorescence in situ hybridization on tissue microarrays. [published erratum appears in Cancer Res 1999 Mar 15; 59(6):1388]. Cancer Res 1999;59(4) 803-806.
6. Scher HI, Sawyers CL. Biology of progressive, castration-resistant prostate cancer: Directed therapies targeting the androgen-receptor signaling axis. J Clin Oncol 2005;23:8253-8261.
7. Culig Z, Hobisch A, Cronauer MV, Radmayr C, Trapman J, Hittmair A, Bartsch G, Klocker H. Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-1, keratinocyte growth factor and epidermal growth factor. Cancer Res 1994;54:5474-5478.
8. Lin J, Adam RM, Santiestevan E, Freeman MR. The phosphatidylinositol 3′-kinase pathway is a dominant growth factor-activated cell survival pathway in LNCaP human prostate carcinoma cells. Cancer Res 1999;59:2891-2897.
9. Petrylak DP, Tangen CM, Hussain MH, Lara PNJ, Jones JA, Taplin ME, Burch PA, Berry D, Moinpour C, Kohli M, Benson MC, Small EJ, Raghavan D, Crawford ED. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004;351:1513-1520.
10. Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, Oudard S, Theodore C, James ND, Turesson I, Rosenthal MA, Eisenberger MA. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004;351:1502-1512.
11. 2+ pathways. Oncogene 1999;18:7860-7872.
12. Miller JR. The Wnts. Genome Biol 2001;3:3001.3001-3001.3015.
13. Shtutman M, Zhurinsky J, Simcha I, Albanese C, D'Amico M, Pestelli R, Ben-Ze'ev A. The cyclin D1 gene is a target of the β-catenin/LEF1 pathway. Proc Natl Acad Sci USA 1999;96:5522-5527.
14. He TC, Sparks AB, Rago C, Hermeking H, Zawel L, da Costa LT, Morin PJ, Vogelstein B, Kinzler KW. Identification of c-MYC as a target of the APC pathway. Science 1998;281:1509-1512.
15. Weeraratna AT, Jiang Y, Hostetter G, Rosenblatt K, Duray P, Bittner M, Trent JM. Wnt5a signaling directly affects cell motility and invasion of metastatic melanoma. Cancer Cell 2002;1:279-288.
16. Civenni G, Holbro T, Hynes NE. Wnt1 and Wnt 5A induce cyclin D1 expression through ErbB1 transactivation in HC11 mammary epithelial cells. EMBO reports 2003;4:166-171.
17. Yook JI, Li X-Y, Ota I, Fearon ER, Weiss SJ. Wnt-dependent regulation of the E-cadherin repressor Snail. J Biol Chem 2005;280:11740-11748.
18. Sharma M, Chuang WW, Sun Z. Phosphatidylinositol 3-kinase/Akt stimulates androgen pathway through GSK3β inhibition and nuclear β-catenin accumulation. J Biol Chem 2002;277:30935-30941.
19. Polakis P. Wnt signaling and cancer. Genes Dev 2000;14:1837-1851.
20. Truica CI, Byers S, Gelmann EP. β-catenin affects androgen receptor transcriptional activity and ligand specificity. Cancer Res 2000;60:4709-4713.
21. Yang F, Li X, Sharma M, Sasaki CY, Longo DL, Lim B, Sun Z. Linking β-catenin to androgen-signaling pathway. J Biol Chem 2002;277:11336-11344.
22. Chesire DR, Dunn TA, Ewing CM, Luo J, Isaacs WB. Identification of aryl hydrocarbon receptor as a putative Wnt/β-catenin pathway target gene in prostate cancer cells. Cancer Res 2004;64:2523-2533.
23. Chesire DR, Ewing CM, Gage WR, Isaacs WB. In vitro evidence for complex modes of nuclear β-catenin signaling during prostate growth and tumorigenesis. Oncogene 2002;21:2629-2694.
24. Chesire DR, Isaacs WB. Ligand-dependent inhibition of β-catenin/TCF signaling by androgen receptor. Oncogene 2002;21:8453-8469.
25. Gounari F, Signoretti S, Bronson R, Klein L, Sellers WR, Kum J, Siermann A, Taketo MM, von Boehmer H, Khazaie K. Stabilization of β-catenin induces lesions reminiscent of prostatic intraepithelial neoplasia, but terminal squamous transdifferentiation of other secretory epithelium. Oncogene 2002;21:4099-4107.
26. Verras M, Brown J, Li X, Nusse R, Sun Z. Wnt3a growth factor induces androgen receptor-mediated transcription and enhances cell growth in human prostate cancer cells. Cancer Res 2004;64:8860-8866.
27. Horvath L, Henshall S, Kench J, Saunders D, Lee C, Golovsky D, Brenner P, O'Neill G, Kooner R, Stricker P, Grygiel J, Sutherland R. Membranous secreted frizzled-related protein 4 predicts for good prognosis in localized prostate cancer and inhibits PC-3 cellular proliferation in vitro. Clin Cancer Res 2004;10:615-625.
28. Song LN, Herrell R, Byers S, Shah S, Wilson EM, Gelmann EP. β-catenin binds to the activation function 2 region of the androgen receptor and modulates the effects of the N-terminal domain and TIF2 on ligand-dependent transcription. Mol Cell Biol 2003;23:1674-1687.
29. Joesting MS, Perrin S, Elenbaas B, Fawell SE, Rubin JS, Franco OE, Hayward SW, Cunha GR. Identification of sFRP1 as a candidate mediator of stromal-to-epithelial signaling in prostate cancer. Cancer Res 2005;65:10423-10430.
30. Zi X, Guo Y, Simoneau AR, Hope C, Xie J, Holcombe RF, Hoang BH. Expression of Frzb/secreted frizzled-related protein 3, a secreted Wnt antagonist, in human androgen-independent prostate cancer PC-3 cells suppresses tumor growth and cellular invasiveness. Cancer Res 2005;65:9762-9770.
31. Price JT, Thompson EW. Models for studying cellular invasion of basement membranes. In: Howlett AR, editor. Methods in Molecular Biology. Totowa, NJ: Humana Press Inc.; 1999. pp 231-249.
32. Horvath L, Henshall S, Lee C, Kench J, Golovsky D, Brenner P, O'Neill G, Kooner R, Stricker P, Grygiel J, Sutherland R. Loss of nuclear beta-catenin predicts for a poorer prognosis in localized prostate cancer. Int J Cancer 2005;113:415-422.
33. Tomita K, van Bokhoven A, van Leenders GJ, Ruijter ET, Jansen CF, Bussemakers MJ, Schalken JA. Cadherin switching in human prostate cancer progression. Cancer Res 2000;60(13) 3650-3654.
34. Melkonyan HS, Chang WC, Shapiro JP, Mahadevappa M, Fitzpatrick PA, Kiefer MC, Tomei LD, Umansky SR. SARPs: A family of secreted apoptosis-related proteins. Proc Natl Acad Sci USA 1997;94:13636-13641.
35. Roth W, Wild-Bode C, Platten M, Grimmel C, Melkonyan HS, Dichgans J, Weller M. Secreted frizzled-related proteins inhibit motility and promote growth of human malignant glioma cells. Oncogene 2000;19:4210-4220.
36. Tian E, Zhan F, Walker R, Rasmussen E, Ma Y, Barlogie B, Shaughnessy JD. The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma. N Engl J Med 2003;349:2483-2494.
37. Hoang BH, Kubo T, Healey JH, Yang R, Nathan SS, Kolb EA, Mazza B, Meyers PA, Gorlick R. Dockkopf 3 inhibits invasion and motility of Saos-2 osteosarcoma cells by modulating the Wnt-beta-catenin pathway. Cancer Res 2004;64:2734-2739.
38. Abu-Jawdeh G, Comella N, Tomita Y, Brown LF, Tognazzi K, Sokol SY, Kocher O. Differential expression of frpHE: A novel human stromal protein of the secreted Frizzled gene family, during the endometrial cycle and malignancy. Lab Invest 1999;79:439-447.
39. Henshall SM, Afar DEH, Rasiah KK, Horvath LG, Gish K, Caras I, Ramakrishnan V, Wong M, Jeffry U, Kench JG, Quinn DI, Turner JJ, Delprado W, Lee C-S, Golovsky D, Brenner PC, O'Neill GF, Kooner R, Stricker PD, Grygiel JJ, Mack DH, Sutherland RL. Expression of the zinc transporter ZnT4 is decreased in the progression from early prostate disease to invasive prostate cancer. Oncogene 2003;22:6005-6012.
40. Henshall SM, Afar DEH, Hiller J, Horvath LG, Quinn DI, Rasiah KK, Gish K, Willhite D, Kench JG, Gardiner-Garden M, Stricker PD, Scher H, Grygiel JJ, Agus DB, Mack DH, Sutherland RL. Survival analysis of genome-wide gene expression profiles of prostate cancers identifies new prognostic targets of disease relapse. Cancer Res 2003;63:4196-4203.
41. Alexander NR, Tran NL, Rekapally H, Summers CE, Glackin C, Heimark RL. N-cadherin gene expression in prostate carcinoma is modulated by integrin-dependent nuclear translocation of Twist1. Cancer Res 2006;66:3365-3369.
42. Gottardi CJ, Gumbiner BM. Distinct molecular forms of beta-catenin are targeted to adhesive or transcriptional complexes. J Cell Biol 2004;167:339-349.
43. Yang X, Chen M-W, Terry S, Vacherot F, Bemis DL, Capodice J, Kitajewski J, de la Taille A, Benson MC, Guo Y, Buttyan R. Complex regulation of human androgen receptor expression by Wnt signaling in prostate cancer cells. Oncogene 2006;25:3436-3444.
44. Zhu H, Mazor M, Kawano Y, Walker MM, Leung HY, Armstrong K, Waxman J, Kypta RM. Analysis of Wnt gene expression in prostate cancer: Mutual inhibition by Wnt11 and the androgen receptor. Cancer Res 2004;64:7918-7926.
45. Maye P, Zheng J, Li L, Wu D. Multiple mechanisms for Wnt11-mediated repression of the canonical Wnt signaling pathway. J Biol Chem 2004;279:24659-24665.
46. Chen G, Shukeir N, Potti A, Sircar K, Aprikian A, Goltzman D, Rabbani S. Up-regulation of Wnt-1 and beta-catenin production in patients with advanced metastatic prostate carcinoma. Cancer 2004;101:1345-1356.
47. Hall CL, Bafico A, Dai J, Aaronson SA, Keller ET. Prostate cancer cells promote osteoblastic bone metastases through wnts. Cancer Res 2005;65:7554-7560.
48. Wissmann C, Wild PJ, Kaiser S, Roepcke S, Stoehr R, Woenckhaus M, Kristiansen G, Hsieh J-C, Hofstaedter F, Hartmann A, Knuechel R, Rosenthal A, Pilarsky C. WIF1, a component of the Wnt pathway, is down-regulated in prostate, breast, lung, and bladder cancer. J Pathol 2003;201:204-212.
49. Ohigashi T, Mizuno R, Nakashima J, Marumo K, Murai M. Inhibition of Wnt signaling downregulates Akt activity and induces chemosensitivity in PTEN-mutated prostate cancer cells. Prostate 2005;62:61-68.